Research programme: human cytomegalovirus inhibitors - WyethAlternative Names: Human cytomegalovirus inhibitors research programme - Wyeth
Latest Information Update: 05 Oct 2006
At a glance
- Originator Wyeth
- Mechanism of Action Cytomegalovirus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 05 Oct 2006 Discontinued - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
- 12 Feb 2002 Preclinical development for Cytomegalovirus infections in USA (Unknown route)